Fly News Breaks for September 6, 2019
Sep 6, 2019 | 06:19 EDT
BofA/Merrill analyst Kevin Fischbeck upgraded HCA Healthcare to Neutral, also raising its price target to $137 from $130. The analyst notes that the company missed its Q2 results with EBITDA reported about $100M below consensus, but after a 15% decline in the stock price ahead of the release, he sees the valuation as "priced to perfection" and risk/reward more balanced at 7.5-times his expected 2020 EBITDA. Fischbeck adds that he expects HCA Healthcare to address the sales mix and earnings shortfall of Q2 faster than expected by the Street.
News For HCA From the Last 2 Days